news 2015-02-05 18:46 ET - News Release
Mr. Robert von der Porten reports
MEDX HEALTH ANNOUNCES A PHARMACY PILOT IN SWEDEN AND DISTRIBUTION AGREEMENT IN AUSTRALIA AND NEW ZEALAND
MedX Health Corp. has given an update on recent business developments, noting that late in 2014, its European pharmacy-focused channel partner commenced a pilot with a pharmacy chain in Sweden. In addition, MedX has signed an exclusive distribution agreement with one of Australia's and New Zealand's leading providers of medical, surgical and health care products to all sectors of these health care markets.
"We are very pleased to be able to expand the distribution of our technology working with our trusted channel partner in Europe for pharmacy-based on-demand skin assessments. They have been successful in building a pharmacy-based cancer-screening business to approximately 100 locations in Norway, and have opened eight pilot locations in a pharmacy chain in Sweden, which has almost twice the population of Norway. One of the pharmacy-based model's features is that MedX earns fee revenue per patient scanned, so this is an attractive market for us in Europe, as well as one we are pursuing in North America," said Rob von der Porten, MedX chief executive officer.
"Furthermore, the finalization of our distribution agreement for Australia and New Zealand with a leading medical distributor to physicians and clinics is a positive development for the company, since this distributor is familiar with our SIAscopy technology. The recent addition of New Zealand to the agreement increases the target market," continued Mr. von der Porten.
Australia and New Zealand together have a population of almost 30 million. Australia has one of the highest rates of skin cancer, accounting for about 80 per cent of all new cancers diagnosed there. Australians are four times more likely to develop a skin cancer than any other form of cancer. Over 750,000 Australians are treated for skin cancer each year.
We seek Safe Harbor.